CN116710121A - 用于治疗实体癌的组合物和方法 - Google Patents

用于治疗实体癌的组合物和方法 Download PDF

Info

Publication number
CN116710121A
CN116710121A CN202180076110.4A CN202180076110A CN116710121A CN 116710121 A CN116710121 A CN 116710121A CN 202180076110 A CN202180076110 A CN 202180076110A CN 116710121 A CN116710121 A CN 116710121A
Authority
CN
China
Prior art keywords
cancer
haloperoxidase
composition
peroxide
oxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076110.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·C·爱伦
J·T·小斯蒂芬斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exoxemis Inc
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of CN116710121A publication Critical patent/CN116710121A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/0101—Chloride peroxidase (1.11.1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180076110.4A 2020-11-11 2021-10-01 用于治疗实体癌的组合物和方法 Pending CN116710121A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112447P 2020-11-11 2020-11-11
US63/112,447 2020-11-11
PCT/US2021/053155 WO2022103515A1 (en) 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
CN116710121A true CN116710121A (zh) 2023-09-05

Family

ID=81601629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076110.4A Pending CN116710121A (zh) 2020-11-11 2021-10-01 用于治疗实体癌的组合物和方法

Country Status (10)

Country Link
US (1) US20230398190A1 (https=)
EP (1) EP4243835A4 (https=)
JP (1) JP2023548406A (https=)
KR (1) KR20230106646A (https=)
CN (1) CN116710121A (https=)
AU (1) AU2021379542A1 (https=)
CA (1) CA3196357A1 (https=)
IL (1) IL302683A (https=)
MX (1) MX2023005171A (https=)
WO (1) WO2022103515A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250332226A1 (en) * 2022-04-13 2025-10-30 Exoxemis, Inc. Compositions and methods for treating solid cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
EP4548978A3 (en) * 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
US10213448B2 (en) * 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US20190271703A1 (en) * 2016-10-26 2019-09-05 Duke University Biomarkers and treatments for metastatic cancer

Also Published As

Publication number Publication date
US20230398190A1 (en) 2023-12-14
WO2022103515A1 (en) 2022-05-19
KR20230106646A (ko) 2023-07-13
CA3196357A1 (en) 2022-05-19
EP4243835A1 (en) 2023-09-20
AU2021379542A1 (en) 2023-06-08
JP2023548406A (ja) 2023-11-16
IL302683A (en) 2023-07-01
AU2021379542A9 (en) 2024-09-05
MX2023005171A (es) 2023-06-26
EP4243835A4 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN101678088B (zh) 修饰的突变体胶原蛋白酶及其在脂肪溶解和疤痕减少中的应用
US20100178273A1 (en) Methods and compositions for treating mucositis
KR20080108996A (ko) 셀룰라이트 치료용 아교질분해효소
KR20130095835A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
Teicher et al. Transforming growth factor-β in in vivo resistance
JP2001511797A (ja) 創傷の治癒
WO2004108088A3 (en) Methods and compositions for interferon therapy
JP2010511039A (ja) 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
CN116710121A (zh) 用于治疗实体癌的组合物和方法
HU215160B (hu) Eljárás humán Cu/Zn szuperoxid dizmutáz előállítására és tisztítására
JP3980088B2 (ja) 傷治癒を改善するプラスミノーゲン活性化因子からなる製剤の使用
EP3710033A1 (en) Nuclear-targeted dna repair enzymes and methods of use
CN119677528A (zh) 用于治疗实体癌的组合物和方法
JP2006505290A (ja) 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
Orgill et al. Debridement of porcine burns with a highly purified, ananain-based cysteine protease preparation
HK40098212A (zh) 用於治疗实体癌的组合物和方法
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
WO2009149201A1 (en) Methods of treatment for pulmonary fibrosis
JP3227673B2 (ja) 膵炎予防治療薬
KR100406268B1 (ko) 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
CN105477627B (zh) 治疗前列腺癌的组合物及其用途
TWI331531B (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
WO2002040498A2 (en) Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides
CN118667809A (zh) 一种抑制jak3基因表达的小干扰核酸和凝胶制剂及其制药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40098212

Country of ref document: HK